Stoke Therapeutics CEO to Present at TD Cowen Health Care Conference
Event summary
- Stoke Therapeutics CEO Ian F. Smith to present at TD Cowen 46th Annual Health Care Conference on March 3, 2026.
- Presentation to be webcast live and archived on Stoke’s investor relations website.
- Stoke’s lead investigational medicine, zorevunersen, is in Phase 3 trials for Dravet syndrome.
- Zorevunersen has received orphan drug, rare pediatric disease, and Breakthrough Therapy designations from FDA and EMA.
- Stoke has a strategic collaboration with Biogen for global commercialization of zorevunersen.
The big picture
Stoke Therapeutics' upcoming presentation at the TD Cowen conference comes as the biotech company advances its lead candidate, zorevunersen, through critical Phase 3 trials. The strategic collaboration with Biogen positions Stoke for potential global expansion, while the company's TANGO approach aims to address a broad range of protein-deficient diseases. The presentation will provide insights into Stoke's execution strategy and the competitive landscape in RNA medicine.
What we're watching
- Clinical Progress
- The pace at which zorevunersen advances through Phase 3 trials and potential regulatory approval timelines.
- Commercial Strategy
- How Stoke and Biogen will navigate global commercialization under their strategic collaboration.
- Market Positioning
- Whether Stoke can maintain its lead in RNA medicine for neurological diseases amid competitive pressures.
Related topics